Retension Pharma Slides 14% in Debut After $45M IPO Priced at $12
RTSN is trading near its 52-week low of $10 (7.7% above the low).
Summary
Retension Pharmaceuticals opened at $10.00, well below its $12.00 IPO price, and fell nearly 14% to $10.36 in early trading. The clinical-stage biotech had upsized the offering to 3.75 million shares from 3.3 million, raising about $45 million at the midpoint of its $11–$13 range. The weak debut signals tepid demand for the new issue despite the upsizing. The stock's first-day performance will be closely watched as a gauge of investor appetite for early-stage biotech IPOs.
At the time of this announcement, RTSN was trading at $10.77 on NASDAQ in the Life Sciences sector. The 52-week trading range was $10.00 to $11.60. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.